Acrivon Therapeutics, Inc. Share Price & Technical Analysis
ACRV · $1.74 (-0.57%)
Healthcare / Biotechnology
$1.74
-0.57%
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprie…
Price chart
Seasonality
May has 0 positive and 4 negative years (last 5 years shown)
-5% return in May, -16% avg return in past 3 year May month.
-18% return in 2026, -30% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -25% | -17% | -7% | 36% | -5% | – | – | – | – | – | – | – | -18% |
| 25 | -2% | -13% | -64% | -30% | -29% | 9% | 8% | 0% | 38% | 11% | 4% | 4% | -61% |
| 24 | -24% | 32% | 33% | 28% | -15% | -27% | 45% | 14% | -26% | 14% | -6% | -22% | 46% |
| 23 | 36% | 7% | -38% | -5% | -5% | 8% | -4% | -5% | -17% | -45% | -23% | 14% | -75% |
| 22 | – | – | – | – | – | – | – | – | – | – | -4% | -8% | -12% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$82.18M
P/E ratio
—
52W high
$3.56
52W low
$1.05
Volume
1,26,079
Beta
2.02
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Acrivon Therapeutics, Inc. share price today?
- Acrivon Therapeutics, Inc. (ACRV) last traded around $1.74 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ACRV have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ACRV. Download the app for real-time alerts.
- How can I analyze Acrivon Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.